• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期食管鳞癌同步放化疗患者总生存预测列线图的建立与验证。

Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.

机构信息

Department of Radiotherapy, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Henan Medical Key Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang 455000, China.

出版信息

Biomed Res Int. 2022 Jul 14;2022:6455555. doi: 10.1155/2022/6455555. eCollection 2022.

DOI:10.1155/2022/6455555
PMID:35872847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9303138/
Abstract

This study aims to develop and validate a effective prognostic nomogram for locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients undergoing concurrent chemoradiotherapy (CCRT). Retrospective analysis of 503 patients with LA-ESCC given CCRT in our hospital from 2009 to 2016 was conducted. Two-thirds of the patients were randomly assigned to the training set ( = 335), and one-third were assigned to the validation set ( = 168). In order to generate the nomogram, multivariate cox regression analysis was undertaken in the training set for uncovering significant prognostic variables for overall survival. The -index and calibration plot were used to verify nomogram discrimination and calibration, respectively. Five independent prognostic variables were found and incorporated into a nomogram: age, N stage, location, tumor response, and MLR (monocyte/lymphocyte ratio). The -indexes of the training set and the validation set were 0.730 and 0.745, respectively. The discrimination and calibration of this nomogram showed good predictive power in both sets. Conclusively, the proposed nomogram may be served as an effective tool for prognostic evaluation of LA-ESCC patients receiving CCRT.

摘要

本研究旨在为接受同期放化疗(CCRT)的局部晚期食管鳞状细胞癌(LA-ESCC)患者开发和验证一种有效的预后列线图。对 2009 年至 2016 年在我院接受 CCRT 的 503 例 LA-ESCC 患者进行回顾性分析。将三分之二的患者随机分配到训练集(n=335),三分之一分配到验证集(n=168)。为了生成列线图,在训练集中进行多变量 Cox 回归分析,以揭示总生存的显著预后变量。使用-指数和校准图分别验证列线图的区分度和校准度。发现了五个独立的预后变量,并将其纳入到一个列线图中:年龄、N 分期、位置、肿瘤反应和 MLR(单核细胞/淋巴细胞比率)。训练集和验证集的-指数分别为 0.730 和 0.745。该列线图在两组中的区分度和校准度均显示出良好的预测能力。总之,该列线图可作为评估接受 CCRT 的 LA-ESCC 患者预后的有效工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/e78b54f648de/BMRI2022-6455555.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/ef84ad80c74d/BMRI2022-6455555.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/59d603827564/BMRI2022-6455555.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/0092089f7cf4/BMRI2022-6455555.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/e78b54f648de/BMRI2022-6455555.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/ef84ad80c74d/BMRI2022-6455555.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/59d603827564/BMRI2022-6455555.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/0092089f7cf4/BMRI2022-6455555.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c354/9303138/e78b54f648de/BMRI2022-6455555.004.jpg

相似文献

1
Development and Validation of a Nomogram for Predicting Overall Survival to Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.局部晚期食管鳞癌同步放化疗患者总生存预测列线图的建立与验证。
Biomed Res Int. 2022 Jul 14;2022:6455555. doi: 10.1155/2022/6455555. eCollection 2022.
2
A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer.基于治疗前 CT 放射组学特征的列线图预测食管鳞癌患者放化疗后完全缓解。
Radiat Oncol. 2020 Oct 29;15(1):249. doi: 10.1186/s13014-020-01692-3.
3
Development and validation of a radiomics-based model to predict local progression-free survival after chemo-radiotherapy in patients with esophageal squamous cell cancer.基于放射组学的模型预测食管鳞癌放化疗后局部无进展生存期的建立和验证
Radiat Oncol. 2021 Oct 12;16(1):201. doi: 10.1186/s13014-021-01925-z.
4
Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.基于治疗前肝肾功能指标的列线图预测新辅助放化疗加手术治疗局部晚期食管鳞癌的生存。
Updates Surg. 2024 Aug;76(4):1377-1388. doi: 10.1007/s13304-023-01693-3. Epub 2023 Nov 13.
5
Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.食管鳞状细胞癌患者新辅助放化疗后病理完全缓解预测列线图的开发
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12519.
6
Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.食管鳞状细胞癌患者接受食管切除术后辅助化疗,针对此前未接受过治疗患者的预后列线图。
Jpn J Clin Oncol. 2016 Apr;46(4):336-43. doi: 10.1093/jjco/hyv206. Epub 2016 Jan 26.
7
Nomogram based on circulating lymphocyte subsets for predicting radiation pneumonia in esophageal squamous cell carcinoma.基于循环淋巴细胞亚群的列线图预测食管鳞癌放射性肺炎。
Front Immunol. 2022 Aug 29;13:938795. doi: 10.3389/fimmu.2022.938795. eCollection 2022.
8
The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.阿帕替尼联合同步放化疗治疗不可手术切除的局部晚期食管鳞状细胞癌患者的安全性和有效性
Med Sci Monit. 2020 Nov 27;26:e927221. doi: 10.12659/MSM.927221.
9
A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.局部晚期食管鳞癌患者同步放化疗后治疗反应的预测模型:基于 SUVmean 和 NLR。
BMC Cancer. 2020 Jun 10;20(1):544. doi: 10.1186/s12885-020-07040-8.
10
Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.食管癌患者的淋巴细胞减少症:与营养不良、各种疾病参数及同步放化疗反应的关系。
Oncologist. 2019 Aug;24(8):e677-e686. doi: 10.1634/theoncologist.2018-0723. Epub 2019 Apr 30.

引用本文的文献

1
Establishing and validating models integrated with hematological biomarkers and clinical characteristics for the prognosis of non-esophageal squamous cell carcinoma patients.建立并验证整合血液生物标志物和临床特征的模型用于非食管鳞状细胞癌患者的预后评估。
Ann Med. 2025 Dec;57(1):2483985. doi: 10.1080/07853890.2025.2483985. Epub 2025 Mar 28.
2
Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study.信迪利单抗为基础的方案治疗晚期食管癌的真实世界疗效和安全性:一项单中心回顾性观察研究。
Biomed Res Int. 2022 Aug 5;2022:7331687. doi: 10.1155/2022/7331687. eCollection 2022.

本文引用的文献

1
Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection.基于影响食管鳞状细胞癌患者根治性切除术后预后的早期复发的定义及危险因素
Transl Oncol. 2021 Jun;14(6):101066. doi: 10.1016/j.tranon.2021.101066. Epub 2021 Mar 18.
2
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer.MIMIC 研究:单核细胞/淋巴细胞比值和乳酸脱氢酶水平在转移性结直肠癌中的预后作用和截断值定义。
Oncologist. 2020 Aug;25(8):661-668. doi: 10.1634/theoncologist.2019-0780. Epub 2020 Mar 23.
3
Nomogram-Integrated C-Reactive Protein/Albumin Ratio Predicts Efficacy And Prognosis In Patients With Thoracic Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy.
列线图整合的C反应蛋白/白蛋白比值预测接受放化疗的胸段食管鳞状细胞癌患者的疗效和预后。
Cancer Manag Res. 2019 Nov 6;11:9459-9468. doi: 10.2147/CMAR.S228113. eCollection 2019.
4
Inflammation and cancer.炎症与癌症。
Environ Health Prev Med. 2018 Oct 20;23(1):50. doi: 10.1186/s12199-018-0740-1.
5
Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis.非转移性食管鳞状细胞癌患者接受根治性同步放化疗时调强放疗与三维适形放疗的比较:一项基于人群的倾向评分匹配分析。
Medicine (Baltimore). 2018 Jun;97(22):e10928. doi: 10.1097/MD.0000000000010928.
6
[Effect of preoperative monocyte-lymphocyte ratio on prognosis of patients with resectable esophagogastric junction cancer].[术前单核细胞与淋巴细胞比值对可切除食管胃交界部癌患者预后的影响]
Zhonghua Zhong Liu Za Zhi. 2017 Mar 23;39(3):178-183. doi: 10.3760/cma.j.issn.0253-3766.2017.03.004.
7
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.中性粒细胞与淋巴细胞比值作为局部晚期食管鳞癌患者接受根治性放化疗的预后生物标志物。
Sci Rep. 2017 Feb 14;7:42581. doi: 10.1038/srep42581.
8
Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study.食管腺癌的多模态治疗:多中心倾向评分匹配研究。
Ann Oncol. 2017 Mar 1;28(3):519-527. doi: 10.1093/annonc/mdw560.
9
Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy.Tie2 在巨噬细胞中的表达对于化疗后血管重建和肿瘤复发是必需的。
Cancer Res. 2016 Dec 1;76(23):6828-6838. doi: 10.1158/0008-5472.CAN-16-1114. Epub 2016 Oct 10.
10
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.